Get started
AKEBIA THERAPEUTICAKEBIA THERAPEUTICAKEBIA THERAPEUTIC

AKEBIA THERAPEUTIC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

AX9 chart


Full chart

AX9 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪352.70 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.187 CHF
Net income (FY)
‪−43.72 M‬ CHF
Revenue (FY)
‪163.86 M‬ CHF
Shares float
‪209.46 M‬
Beta (1Y)
3.01

Employees


Employees (FY)
167
Change (1Y)
−38 −18.54%
Revenue / Employee (1Y)
‪981.20 K‬ CHF
Net income / Employee (1Y)
‪−261.78 K‬ CHF

About Akebia Therapeutics, Inc.


Sector
Health Technology
CEO
John P. Butler
Headquarters
Cambridge
Website
akebia.com
Founded
2007
FIGI
BBG00LVD5GC6
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AX9 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of AX9 is 1.900 CHF — it has increased by 0.80% in the past 24 hours. Watch AKEBIA THERAPEUTIC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange AKEBIA THERAPEUTIC stocks are traded under the ticker AX9.
AX9 stock has risen by 0.80% compared to the previous week, the month change is a 0.80% rise, over the last year AKEBIA THERAPEUTIC has showed a 0.80% increase.
We've gathered analysts' opinions on AKEBIA THERAPEUTIC future price: according to them, AX9 price has a max estimate of 9.16 CHF and a min estimate of 3.66 CHF. Watch AX9 chart and read a more detailed AKEBIA THERAPEUTIC stock forecast: see what analysts think of AKEBIA THERAPEUTIC and suggest that you do with its stocks.
AX9 reached its all-time high on Sep 20, 2021 with the price of 2.650 CHF, and its all-time low was 1.885 CHF and was reached on Jan 25, 2022. View more price dynamics on AX9 chart.
See other stocks reaching their highest and lowest prices.
AX9 stock is 1.89% volatile and has beta coefficient of 3.01. Track AKEBIA THERAPEUTIC stock price on the chart and check out the list of the most volatile stocks — is AKEBIA THERAPEUTIC there?
Today AKEBIA THERAPEUTIC has the market capitalization of ‪352.70 M‬, it has decreased by −1.99% over the last week.
Yes, you can track AKEBIA THERAPEUTIC financials in yearly and quarterly reports right on TradingView.
AKEBIA THERAPEUTIC is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
AX9 earnings for the last quarter are −0.08 CHF per share, whereas the estimation was −0.05 CHF resulting in a −57.90% surprise. The estimated earnings for the next quarter are −0.07 CHF per share. See more details about AKEBIA THERAPEUTIC earnings.
AKEBIA THERAPEUTIC revenue for the last quarter amounts to ‪31.72 M‬ CHF, despite the estimated figure of ‪37.71 M‬ CHF. In the next quarter, revenue is expected to reach ‪33.91 M‬ CHF.
AX9 net income for the last quarter is ‪−16.98 M‬ CHF, while the quarter before that showed ‪−7.72 M‬ CHF of net income which accounts for −120.10% change. Track more AKEBIA THERAPEUTIC financial stats to get the full picture.
No, AX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 22, 2025, the company has 167.00 employees. See our rating of the largest employees — is AKEBIA THERAPEUTIC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AKEBIA THERAPEUTIC EBITDA is ‪2.40 M‬ CHF, and current EBITDA margin is −2.17%. See more stats in AKEBIA THERAPEUTIC financial statements.
Like other stocks, AX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AKEBIA THERAPEUTIC stock right from TradingView charts — choose your broker and connect to your account.